Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (151-160 of 440) with videos related to

Pageof 44
Sort By:
Blood|March 29, 2007
14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cellsShaozhong Dong, Sumin Kang, Ting-Lei Gu, et al.
Infection Control and Hospital Epidemiology|March 24, 2017
Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National StudyNishi N Shah, William McClellan, Christopher R Flowers, et al.
Cancer|November 8, 2014
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patientsMeagan S Barbee, Ajay Nooka, Jonathan L Kaufman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 1, 2004
A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell productsSagar Lonial, Michelle Hicks, Hilary Rosenthal, et al.
Blood Advances|January 4, 2018
CD86 regulates myeloma cell survivalCatherine M Gavile, Benjamin G Barwick, Scott Newman, et al.
International Journal of Hematology|July 4, 2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myelomaAsher A Chanan-Khan, Sagar Lonial, Donna Weber, et al.
Blood|February 3, 2017
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myelomaVikas A Gupta, Shannon M Matulis, Jason E Conage-Pough, et al.
Leukemia & Lymphoma|October 31, 2006
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphomaSagar Lonial, Martha Arellano, Donald Hutcherson, et al.
Cancer|May 16, 2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patientsAjay K Nooka, Nisha S Joseph, Jonathan L Kaufman, et al.
The Oncologist|January 13, 2006
A practical update on the use of bortezomib in the management of multiple myelomaJesús San Miguel, Joan Bladé, Mario Boccadoro, et al.
Pageof 44

Showing results (151-160 of 440) with videos related to

Sort By:
Pageof 44
Blood|March 29, 2007
14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cellsShaozhong Dong, Sumin Kang, Ting-Lei Gu, et al.
Infection Control and Hospital Epidemiology|March 24, 2017
Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National StudyNishi N Shah, William McClellan, Christopher R Flowers, et al.
Cancer|November 8, 2014
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patientsMeagan S Barbee, Ajay Nooka, Jonathan L Kaufman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 1, 2004
A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell productsSagar Lonial, Michelle Hicks, Hilary Rosenthal, et al.
Blood Advances|January 4, 2018
CD86 regulates myeloma cell survivalCatherine M Gavile, Benjamin G Barwick, Scott Newman, et al.
International Journal of Hematology|July 4, 2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myelomaAsher A Chanan-Khan, Sagar Lonial, Donna Weber, et al.
Blood|February 3, 2017
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myelomaVikas A Gupta, Shannon M Matulis, Jason E Conage-Pough, et al.
Leukemia & Lymphoma|October 31, 2006
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphomaSagar Lonial, Martha Arellano, Donald Hutcherson, et al.
Cancer|May 16, 2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patientsAjay K Nooka, Nisha S Joseph, Jonathan L Kaufman, et al.
The Oncologist|January 13, 2006
A practical update on the use of bortezomib in the management of multiple myelomaJesús San Miguel, Joan Bladé, Mario Boccadoro, et al.
Pageof 44